Nit

Monitoring Patient Glucose Levels: New Advances in software make it easier

Monitoring patient glucose levels and determining the response to intervention is critical when working with diabetic clients. The benefit of doing so in improved outcomes for both type 1 and type 2 diabetes has been clearly established by clinical trials conducted in both the U.S. and the UK1. Self- monitoring by patients of glucose levels, and the data provided is especially important for p...

Monitoring Options Expand for Therapeutic Agents and Drugs of Abuse

In keeping with the recent proliferation of rapid, easy-to-use diagnostic tests, many assays and collection products have entered the marketplace to help clinicians assess dosage appropriateness of therapeutic drugs and to screen for the presence of drugs of abuse. Some of these products require laboratory support while many simple test kits are suitable for point of care use by medical profe...

Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference

MALVERN, Pa., June 28, 2007 /PRNewswire-FirstCall/ -- AuxiliumPharmaceuticals, Inc. today announced that Mr. Armando Anido, ChiefExecutive Officer and President, and Mr. Jim Fickenscher, ChiefFinancial Officer, will participate in the 2007 CEUT EmergingGrowth Opportunities Conference to be held July 10 through July 12,2007 at the Mandarin Oriental Hotel in New York City. Mr. Anido issche...

ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 2, 2007 - ViaCell, Inc.(NASDAQ: VIAC) today announced that Marc D. Beer, President andChief Executive Officer of ViaCell, will present an update on itsbusiness activities and product pipeline at the C.E. Unterberg,Towbin Emerging Growth Opportunities Conference on Tuesday, July10, 2007 at 3:00 p.m. at the Mandarin Oriental Hotel in New York,NY. A live...

Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference

SAN DIEGO--(BUSINESS WIRE)--Jul 2, 2007 - Accelrys, Inc.(NASDAQ:ACCL), the leading provider of scientific businessintelligence software and services, announced today that its CFO,Rick Russo, will present at the C.E. Unterberg, Towbin EmergingGrowth Opportunities Conference in New York on July 11, 2007 at10:30 a.m. ET. The conference will take place at the MandarinOriental Hotel July 10th-12...

Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

DURHAM, N.C.--(BUSINESS WIRE)--Jul 3, 2007 - InspirePharmaceuticals, Inc. (NASDAQ:ISPH) announced today that Christy L.Shaffer, Ph.D., President and CEO, will present at the C.E.Unterberg, Towbin Emerging Growth Opportunities Conference onWednesday, July 11, 2007 at 11:00 am ET in New York City. The webcast of the presentation will be available on Inspire'sweb site at www.inspirepharm.com...

EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Jul 3, 2007 - EPIXPharmaceuticals, Inc. (NASDAQ:EPIX) today announced that Michael G.Kauffman, M.D., Ph.D., chief executive officer of EPIX, isscheduled to present at the C.E. Unterberg, Towbin Emerging GrowthOpportunities Conference on Tuesday, July 10, 2007 at 1:30 p.m.(EDT) at the Mandarin Oriental Hotel in New York, NY. The presentation will be webca...

Rosetta Genomics to Webcast Presentation at CE Unterberg, Towbin Emerging Growth Opportunities Conference

REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, July 03, 2007/PRNewswire-FirstCall/ -- Rosetta Genomics Ltd , a leading microRNAcompany, announced today that J. Michael French, Rosetta GenomicsPresident, will present at CE Unterberg, Towbin Emerging GrowthOpportunities Conference on Tuesday, July 10, at 11:00 am EST atthe Mandarin Oriental Hotel in New York. A live audio webcast o...

GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Jul 5, 2007 - GTCBiotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced today thatGeoffrey Cox, Ph.D., GTC's Chairman and CEO, is scheduled topresent on Wednesday, July 11, 2007 at 9:00 a.m. during the C.E.Unterberg, Towbin Emerging Growth Life Opportunities Conference.The conference is being held at the Mandarin Oriental Hotel, NewYork, New York from July...

Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

BLOOMFIELD, N.J., July 05, 2007 /PRNewswire/ -- AlfacellCorporation today announced that Lawrence A. Kenyon, executive vicepresident, chief financial officer and corporate secretary, willpresent an overview of the company's product development programsat 8 a.m. EDT on Thursday, July 12, 2007, at the C.E. Unterberg,Towbin Emerging Growth Opportunities Conference in New York. The aud...

SuperGen to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

DUBLIN, Calif., July 06, 2007 /PRNewswire-FirstCall/ --SuperGen, Inc. today announced that Dr. Gregory Berk, Chief MedicalOfficer, will present at the C.E. Unterberg, Towbin Emerging GrowthOpportunities Conference on Thursday, July 12, 2007 at the MandarinOriental Hotel in New York City. SuperGen's presentation at the C.E. Unterberg, Towbin EmergingGrowth Opportunities Conference i...

ZIOPHARM to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

NEW YORK--(BUSINESS WIRE)--Jul 6, 2007 - ZIOPHARM Oncology, Inc.(NASDAQ: ZIOP) announced today that Dr. Jonathan Lewis, ChiefExecutive Officer, will present at the C.E. Unterberg, TowbinEmerging Growth Opportunities Conference on Thursday, July 12, 2007at 2:30 p.m. ET at the Mandarin Oriental Hotel, New York. Dr. Lewiswill provide an overview of the Company and an update on itsclinical deve...

Neose Technologies to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

HORSHAM, Pa.--(BUSINESS WIRE)--Jul 9, 2007 - Neose Technologies,Inc. (NasdaqGM:NTEC) announced today that it will present at theC.E. Unterberg, Towbin Emerging Growth Opportunities Conferenceheld at the Mandarin Oriental Hotel in New York City from July10-12, 2007. The Company's presentation is scheduled for 2:00 p.m.(EDT) on Tuesday, July 10, 2007. The presentation will be webcastlive and...

Icagen to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Jul 9, 2007 -Icagen, Inc. (NASDAQ: ICGN) today announced that P. Kay Wagoner,Ph.D., Chief Executive Officer, will present at the C.E. Unterberg,Towbin Emerging Growth Opportunities Conference in New York City onThursday, July 12th at 2:00 p.m. ET. There will be a live webcast of this presentation from theconference. The webcast will be access...

Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis

IRVINE, Calif.--(BUSINESS WIRE)--Jul 6, 2007 - Cobalis Corp.(OTCBB:CLSC), a pharmaceutical development company specializing inanti-allergy medications, today reported preliminary top-lineresults from two Phase III clinical trials for its drugPreHistin(TM) in patients with moderate to moderately severeseasonal allergic rhinitis, commonly known as hay fever. The trialsshowed very low symptom...

An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes

CHICAGO--(BUSINESS WIRE)--Jun 25, 2007 - New data from aninvestigational study released at the American Diabetes Association(ADA) 67th Annual Scientific Sessions showed that initialcombination therapy with Januvia(TM) (sitagliptin) and metformindemonstrated significant improvement in markers of beta cellfunction in patients with type 2 diabetes. Pancreatic islet betacell function determines...

Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis

RESEARCH TRIANGLE PARK, N.C. & SHERBROOKE, Quebec--(BUSINESSWIRE)--Jun 26, 2007 - Tranzyme Pharma, a leading biopharmaceuticalcompany developing small molecule drugs for the treatment ofgastrointestinal and metabolic diseases, today announced positiveresults for its novel ghrelin agonist, TZP-101, in acceleratinggastric emptying in diabetic patients with gastroparesis. The datafrom a pi...

Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes

CHICAGO--(BUSINESS WIRE)--Jun 23, 2007 - Late breaking datapresented at the American Diabetes Association (ADA) 67th AnnualScientific Sessions showed that, when used investigationally asinitial therapy, JANUVIA(TM) (sitagliptin) in combination withmetformin provided significant glycemic improvement and wasgenerally well tolerated over 54 weeks in patients with type 2diabetes. Additional new...

Malvern initiates European user group meetings for chemical imaging

WORCESTERSHIRE , England, 21 June 2007, Malvern Instruments hasheld the inaugural meeting in Europe for users of the company'snear infrared chemical imaging (NIR-CI) systems. The one-day event,which took place on 13 June 2007 was hosted by AstraZeneca inMacclesfield, UK. Malvern customers from some of the world's majorpharmaceutical companies joined Malvern's technical and scientificteam...

MAP Pharmaceuticals to Present Unit Dose Budesonide Phase 2 Clinical Data at the World Asthma Meeting

MOUNTAIN VIEW, Calif., June 22, 2007 /PRNewswire/ -- MAPPharmaceuticals, Inc. today announced that it will present Phase 2data from its Unit Dose Budesonide (UDB) pediatric asthma therapyclinical program at the World Asthma Meeting at the Lutfi KirdarConvention and Exhibition Center in Istanbul, Turkey. The oral and poster presentation entitled, "Efficacy and safetyof a novel submi...

Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Women's Health Initiative Data

Fourth Study to Indicate that Early Use of Estrogen May beCardio-Protective PHOENIX, June 20, 2007 /PRNewswire-USNewswire/ -- A new analysisof Women's Health Initiative data published in the New EnglandJournal of Medicine, shows significant reduction in calcifiedplaque for women aged 50 to 59 using hormone therapy (HT) comparedwith women taking a placebo. This is the first time therelati...

New Flu Vaccine from PepTcell Could Provide Immunity Against All Strains of Influenza Virus

HIGH WYCOMBE, UK 18th June 2007-Previously undisclosedpre-clinical data showing how a new flu vaccine has the potentialto protect against all strains of influenza, including pandemic andannual, was presented today by PepTcell, at the 2007 Options forthe Control of Influenza VI (Options) Conference, in Toronto,Canada. The pre-cli...

New Flu Vaccine From PepTcell Could Provide Immunity Against All Strains of Influenza Virus

Data Presented at Leading Influenza Conference HIGH WYCOMBE, England, June 18, 2007 /PRNewswire/ -- Previouslyundisclosed pre-clinical data showing how a new flu vaccine has thepotential to protect against all strains of influenza, includingpandemic and annual, was presented today by PepTcell, at the 2007Options for the Control of Influenza VI (Options) Conference, inToronto, Canada....

Indevus Announces Presentation of Pagoclone Data at 47th Annual New Clinical Drug Evaluation Unit Meeting

Open-label Extension of Phase II Study Demonstrates SignificantAdditional Improvement for Patients on Pagoclone LEXINGTON, Mass., June 12, 2007 /PRNewswire-FirstCall/ --Indevus Pharmaceuticals, Inc. today announced that results from theCompany's Phase II EXPRESS trial for pagoclone in persistentdevelopmental stuttering will be presented today at the 47th annualmeeting of the New Clinical...

July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia

WALTHAM, Mass.--(BUSINESS WIRE)--Jun 12, 2007 - Results from thesuccessful clinical trial of Oscient Pharmaceuticals' (Nasdaq:OSCI) FACTIVE(R) (gemifloxacin mesylate) tablets for the five-daytreatment of community-acquired pneumonia of mild to moderateseverity (CAP) have been published in the July issue of thepeer-reviewed Journal of Antimicrobial Chemotherapy, currentlyavailable in advance...

Data Showing that ReGen's Colostrinin Supports Healthy Cognitive Function Presented at the 2007 International Congress on Natural Medicine in Australia

London, UK, June 11, 2007-ReGen is pleased to announce thata review of scientific and clinical information on Colostrinin, itsnutraceutical product which the Company believes has the potentialto support healthy cognitive function, was presented today at the2007 International Congress on Natural Medicine in SurfersParadise, Queensland, Australia by Dr Marian Kruzel, ReGen's ChiefScientifi...

Promising Data on Cognitive Effects of Safinamide in Early Parkinson's Disease

• Data presented at Movement Disorder Society’s 11thInternational Congress • Management of cognitive impairment in earlyParkinson’s disease patients is a critical unmet medicalneed Geneva, Switzerland, June 8, 2007 – Merck Serono S.A.(virt-x: SEO) and its partner Newron Pharmaceuticals S.p.a. (SWX:NWRN) announced today data, which suggest tha...

Immunomedics Reports Initial Clinical Results With Hpam4 For Pancreatic Cancer Therapy

- Results Presented at Society of Nuclear Medicine Annual Meeting - WASHINGTON, June 05, 2007 /PRNewswire-FirstCall/ --Immunomedics, Inc. , a biopharmaceutical company focused ondeveloping monoclonal antibodies to treat cancer and other seriousdiseases, today announced that initial results from a Phase I studywith the Company's humanized anti-MUC1 monoclonal antibody (hPAM4),labeled with...

Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting

Data From the Companies' Novel Heat Shock Protein 90 InhibitorReveal Further Evidence of Safety, Tolerability, and BiologicalActivity CAMBRIDGE, Mass. and GAITHERSBURG, Md., June 5, 2007 (PRIMENEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) andMedImmune, Inc. (Nasdaq:MEDI) today announced updated interimresults from a Phase I clinical trial of the companies' heat shockpr...

Vision Deficit in Retinitis Pigmentosa Mice Corrected with DNA Nanoparticles

CLEVELAND--(BUSINESS WIRE)--Jun 4, 2007 - Copernicus Therapeutics,Inc. announced today that a research team at University of OklahomaHealth Sciences Center, led by Dr. Muna Naash, Professor of CellBiology, demonstrated that Copernicus' DNA nanoparticles correctedvision defects in a mouse model of retinitis pigmentosa (RP). Thesefindings were presented at the American Society of Gene Therapy...

Phase 2 Clinical Results of Ganite Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO

BERKELEY HEIGHTS, NJ – June 4, 2007 – GentaIncorporated (Nasdaq: GNTA) announced the presentation of resultsfrom a Phase 2 clinical trial of its marketed product, Ganite®(gallium nitrate injection), plus rituximab (Rituxan®;Genentech/IDEC) and dexamethasone in patients with relapsed orrefractory non-Hodgkin’s lymphoma (NHL). The data werepresented at the annual mee...

Phase 2 Clinical Results of Ganite Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO

BERKELEY HEIGHTS, N.J., June 04, 2007 /PRNewswire-FirstCall/ --Genta Incorporated announced the presentation of results from aPhase 2 clinical trial of its marketed product, Ganite(R) (galliumnitrate injection), plus rituximab (Rituxan(R); Genentech/IDEC) anddexamethasone in patients with relapsed or refractory non-Hodgkin'slymphoma (NHL). The data were presented at the annual meeting of...

Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO

CAMBRIDGE, Mass. and GAITHERSBURG, Md., May 31, 2007 (PRIMENEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) andMedImmune, Inc. (Nasdaq:MEDI) today announced that interim clinicaldata on IPI-504 in a Phase I trial in patients withgastrointestinal stromal tumors (GIST) and other soft tissuesarcomas (STS), will be presented at the 2007 Annual Meeting of theAmerican Society of Clini...

Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term Protection and Sterilizing Immunity in Nonhuman Primates

SEATTLE, May 31, 2007 /PRNewswire-FirstCall/ -- VicalIncorporated today announced that a measles DNA vaccine formulatedwith the company's Vaxfectin(TM) adjuvant elicited protectivelevels of neutralizing antibodies in juvenile (1 - 2 year old)nonhuman primates confirmed by complete protection followingchallenge more than one year after vaccination, and sterilizingimmunity as evidenced by...

Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD

Phase III clinical trial may commence shortly CARMIEL, Israel, April 18, 2007 /PRNewswire-FirstCall/ ---Protalix BioTherapeutics, Inc. today announced that it has receivedwritten notice from the United States Food and Drug Administration(FDA) that it may initiate a Phase III clinical trial in the UnitedStates of its lead product candidate, prGCD, a proprietary plantcell expressed recombin...

Inspire Announces Positive Results of Phase 2 Trial of Epinastine Nasal Spray for Seasonal Allergic Rhinitis

DURHAM, N.C.--(BUSINESS WIRE)--May 8, 2007 - InspirePharmaceuticals, Inc. (NASDAQ: ISPH) today announced results of aPhase 2 dose-ranging clinical trial comparing epinastine nasalspray and placebo in patients with seasonal allergic rhinitis. Forthe primary endpoint of improvement in total nasal symptom score,dose-related effects were observed in the trial, with the higherdose (0.1%) achievi...

EPIX Pharmaceuticals Announces Statistically Significant Results in Cognitive Function from Phase 1b Clinical Trial of Novel 5-HT6 Drug Candidate

LEXINGTON, Mass.--(BUSINESS WIRE)--Apr 18, 2007 - EPIXPharmaceuticals, Inc. (NASDAQ: EPIX) announced today positivecognitive function results from its Phase 1b multiple ascendingdose clinical trial of PRX-07034, the company'sinternally-discovered, novel 5-HT6 antagonist being developed forobesity, Alzheimer's disease and cognitive impairment associatedwith schizophrenia. The randomized,...

Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial

PS433540 Shown to Be Well Tolerated and Potentially Suited for OnceDaily Administration PRINCETON, N.J., April 10, 2007 /PRNewswire-FirstCall/ --Pharmacopeia , an innovator in the discovery and development ofnovel small molecule therapeutics, today announced positive resultsfrom the initial Phase 1 clinical trial of PS433540, the company'slead internal product candidate for the treatment...

Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR

Infinity and MedImmune to Present Preclinical Data From Study ofOral Formulation of IPI-504 At AACR CAMBRIDGE, Mass. and GAITHERSBURG, Md., April 10, 2007 (PRIMENEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) andMedImmune, Inc. (Nasdaq:MEDI) today announced that data from apreclinical study with an oral formulation of IPI-504 in non-smallcell lung cancer (NSCLC) will be presente...

Over 10,000 UK Breast Cancer Patients Could Become Eligible Within the Next Year for a Breast Cancer Therapy Showing Increased Survival Rates, Reveals Synovate Healthcare’s European Oncology Monitor

LONDON, April 4, 2007--Treatment data fromSynovate Healthcare’s European Oncology Monitor reveals thatover 10,000 breast cancer patients in the UK could become eligiblefor a breast cancer treatment showing lower death rates inpatients. The treatment was the subject of a recent study detailedin the online edition of The Lancet (12 February 2007). Lowermortality rates we...